New non-executive director for Nuclera
Cambridge-based biotechnology company Nuclera has appointed William J. Kullback to its board of directors as a non-executive director.
William J. Kullback joined Nuclera as a non-executive director in mid-February. He is a seasoned executive with extensive financial experience from several medical device and life science companies. He joins UK-based Nuclera at a pivotal time as the company plans to continue its global commercial expansion strategy following a successful $75 million Series C closing.
Kullback previously served as CFO of Telesis Bio, a company specializing in automated synthesis technology for therapeutic research. Previously, he was CFO at BioLegend Inc, a global provider of antibodies and life science reagents, where he oversaw the sale of the company to Revvity (formerly PerkinElmer) for $5.25 billion.
Prior to its acquisition by Shanghai-based MicroPort Sciencific Corporation, Kullback was CFO of NASDAQ-listed Lombard Medical.
Sphere Fluidics